**Percutaneous Vertebroplasty and Sacroplasty**

<table>
<thead>
<tr>
<th>Original Policy Date:</th>
<th>February 14, 2011</th>
<th>Effective Date:</th>
<th>June 1, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section:</td>
<td>6.0 Radiology</td>
<td>Page:</td>
<td>Page 1 of 30</td>
</tr>
</tbody>
</table>

### Policy Statement

I. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of any of the following indications:
   A. Symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (e.g., analgesics, physical therapy, and rest) for at least 6 weeks
   B. Severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies
      1. Vertebral eosinophilic granuloma with spinal instability
      2. Vertebral hemangiomas with **both** of the following:
         a. Aggressive signs (e.g., myelopathy, radiculopathy, bone fracture, collapse or destruction)
         b. Radiation therapy has failed to relieve symptoms

II. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that are less than 6 weeks in duration that have led to hospitalization or persist at a level that prevents ambulation.

III. Percutaneous vertebroplasty is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

IV. Percutaneous sacroplasty is considered **investigational** for all indications, including use in **either** of the following:
   A. Sacral insufficiency fractures due to osteoporosis
   B. Sacral lesions due to multiple myeloma or metastatic malignancies

**NOTE:** Refer to Appendix A to see the policy statement changes (if any) from the previous version.

### Policy Guidelines

**Coding**

There are CPT codes that describe vertebroplasty:

- **22510:** Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic
- **22511:** Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral
- **22512:** Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure)

**Effective January 1, 2023,** there are two new HCPCS code that represents vertebroplasties:

- **C7504:** Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance
- **C7505:** Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance
The following are CPT category III codes for sacroplasty:

- **0200T**: Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed
- **0201T**: Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed

**Description**

Percutaneous vertebroplasty is an interventional technique involving the fluoroscopically guided injection of polymethylmethacrylate into a weakened vertebral body. The technique has been investigated to provide mechanical support and symptomatic relief in patients with osteoporotic vertebral compression fractures or those with osteolytic lesions of the spine (e.g., multiple myeloma, metastatic malignancies); as a treatment for sacral insufficiency fractures; and as a technique to limit blood loss related to surgery.

**Related Policies**

- N/A

**Benefit Application**

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

Vertebroplasty is a surgical procedure and, as such, is not subject to U.S. Food and Drug Administration (FDA) approval.

Polymethylmethacrylate bone cement was available as a drug product before enactment of the FDA’s device regulation and was at first considered what the FDA terms a “transitional device.” It was transitioned to a class III device requiring premarketing applications. Several orthopedic companies have received approval of their bone cement products since 1976. In 1999, polymethylmethacrylate was reclassified from class III to class II, which requires future 510(k) submissions to meet “special controls” instead of “general controls” to assure safety and effectiveness. Thus, use of polymethylmethacrylate in vertebroplasty represented an off-label use of an FDA-regulated product before 2005. In 2005, polymethylmethacrylate bone cements such as Spine-Fix® Biomimetic Bone Cement and Osteopal® V were cleared for marketing by the FDA through the 510(k) process for the fixation of pathologic fractures of the vertebral body using vertebroplasty procedures.

The use of polymethylmethacrylate in sacroplasty is an off-label use of an FDA-regulated product (bone cements such as Spine-Fix® Biomimetic Bone Cement [Teknimed] and Osteopal® V [Heraeus])
because the 510(k) approval was for the fixation of pathologic fractures of the vertebral body using vertebroplasty procedures. Sacroplasty was not included. FDA product code: NDN.

In 2009, Cortoss® (Stryker) Bone Augmentation Material was cleared for marketing by the FDA through the 510(k) process. Cortoss® is a nonresorbable synthetic material that is a composite resin-based, bis-glycidyl dimethacrylate. The FDA classifies this product as a polymethyl methacrylate bone cement.

In 2010, the Parallax® Contour® Vertebral Augmentation Device (ArthroCare) was cleared for marketing by FDA through the 510(k) process. The device creates a void in cancellous bone that can then be filled with bone cement. FDA product code: HXG.

### Rationale

#### Background

**Treatment of Vertebral Compression Fracture**
Chronic symptoms do not tend to respond to the management strategies for acute pain such as bed rest, immobilization or bracing device, and analgesic medication, sometimes including narcotic analgesics. The source of chronic pain after vertebral compression fracture may not be from the vertebra itself but may be predominantly related to strain on muscles and ligaments secondary to kyphosis. This type of pain frequently does not improve with analgesics and may be better addressed through exercise or physical therapy. Improvements in pain and ability to function are the principal outcomes of interest for treatment of osteoporotic fractures.

**Treatment of Sacral Insufficiency Fractures**
Similar interventions are used for sacral and vertebral fractures and include bed rest, bracing, and analgesics. Initial clinical improvements may occur quickly; however, resolution of all symptoms may not occur for 9 to 12 months.

**Vertebral and Sacral Body Metastasis**
Metastatic malignant disease of the spine generally involves the vertebrae/sacrum, with pain being the most frequent complaint.

**Treatment of Vertebral and Sacral Body Metastasis**
While radiotherapy and chemotherapy are frequently effective in reducing tumor burden and associated symptoms, pain relief may be delayed days to weeks, depending on tumor response. Further, these approaches rely on bone remodeling to regain strength in the vertebrae/sacrum, which may necessitate supportive bracing to minimize the risk of vertebral/sacral collapse during healing. Improvements in pain and function are the primary outcomes of interest for treatment of bone malignancy with percutaneous vertebroplasty or sacroplasty.

#### Surgical Treatment Options

**Percutaneous Vertebroplasty**
Vertebroplasty is a surgical procedure that involves the injection of synthetic cement (e.g., polymethylmethacrylate, bis-glycidal dimethacrylate [Cortoss]) into a fractured vertebra. It has been suggested that vertebroplasty may provide an analgesic effect through mechanical stabilization of a fractured or otherwise weakened vertebral body. However, other mechanisms of effect have been postulated, including thermal damage to intraosseous nerve fibers.

**Percutaneous Sacroplasty**
Sacroplasty evolved from the treatment of insufficiency fractures in the thoracic and lumbar vertebrae with vertebroplasty. The procedure, essentially identical to vertebroplasty, entails guided injection of polymethylmethacrylate through a needle inserted into the fracture zone. Although first
described in 2000 as a treatment for symptomatic sacral metastatic lesions, it is most often described as a minimally invasive alternative to conservative management for sacral insufficiency fractures.

Pain and function are subjective outcomes and, thus, may be susceptible to placebo effects. Furthermore, the natural history of pain and disability associated with these conditions may vary. Therefore, controlled comparison studies would be valuable to demonstrate the clinical effectiveness of vertebroplasty and sacroplasty over and above any associated nonspecific or placebo effects and to demonstrate the effect of treatment compared with alternatives such as continued medical management.

In all clinical situations, adverse events related to complications from vertebroplasty and sacroplasty are the primary harms to be considered. Principal safety concerns relate to the incidence and consequences of leakage of the injected polymethyl methacrylate or another injectate.

**Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGTBQIA [Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual]; Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

**Percutaneous Vertebroplasty for Vertebral Compression Fractures of Between 6 Weeks and 1 Year Old**

**Clinical Context and Therapy Purpose**

Osteoporotic compression fractures are common. It is estimated that up to one-half of women and approximately one-quarter of men will have a vertebral fracture at some point in their lives. However, only about one-third of vertebral fractures reach clinical diagnosis, and most symptomatic fractures will heal within a few weeks or 1 month with medical management. Nonetheless, some individuals with acute fractures will have severe pain and decreased function that interferes with the ability to ambulate and is not responsive to usual medical management. Also, a minority of patients will exhibit chronic pain following osteoporotic compression fracture that presents challenges for medical management.
The purpose of vertebroplasty is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with symptomatic osteoporotic or osteolytic vertebral fractures between 6 weeks and 1 year old.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is individuals with symptomatic osteoporotic or osteolytic vertebral fractures between 6 weeks and 1 year old. With acute fractures, these individuals experience severe pain, decreased ambulatory function, and a lessened response to conservative medical management. Risk factors for osteoporotic or osteolytic vertebral fractures can include osteopenia, osteoporosis, advanced age, inactivity, corticosteroid use, female sex, and depression.

**Interventions**
The therapy being considered is vertebroplasty, a procedure for stabilizing compression fractures in the spine, during which bone cement is injected into the fractured vertebra through a small hole in the skin in order to relieve back pain.

**Comparators**
Comparators of interest include conservative management. Conservative management includes measures to reduce pain and improve mobility. Physical therapy, analgesics, narcotics, and hormone treatments can be prescribed to achieve this. Bed rest and braces may also be utilized as conservative management; however, these modalities are associated with prolonged immobilization which can further exacerbate bone loss and fail to relieve symptoms.

**Outcomes**
The general outcomes of interest are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Negative outcomes can include complications with sedation, further injury during transfer to the radiology table, and the possibility of abuse after the prescription of narcotics. The outcomes of interest for vertebroplasty as a treatment for symptomatic vertebral fractures have varying follow-up times to fully examine the impact on the patient, ranging from shorter term outcomes like medication use to outcomes that require extended follow-up, such as functional outcomes. Given that the existing literature evaluating vertebroplasty as a treatment for symptomatic vertebral fractures between 6 weeks and 1 year old has varying lengths of follow-up, ranging from 6 months to 2 years, follow-up timing of 1 year is appropriate to demonstrate efficacy. Disability, a major factor on quality of life, is measured using various tools throughout the literature.

Three such tools include the Roland-Morris Disability Questionnaire, the visual analogue scale, and QUALEFFO (a quality of life questionnaire in patients with vertebral fractures). The Roland-Morris Disability Questionnaire is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale and on visual analogue scale. The Roland-Morris Disability Questionnaire has been shown to yield reliable measurements, which are valid for inferring the level of disability, and to be sensitive to change over time for groups of patients with low back pain. Visual analogue scale is commonly used as the outcome measure for such studies. It is usually presented as a 100-mm horizontal line on which the patient’s pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable." With QUALEFFO (a quality of life questionnaire in patients with vertebral fractures), quality of life is measured by the scale 0 to 100, higher scores indicating worse quality of life.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:
1. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
2. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

3. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

4. Studies with duplicative or overlapping populations were excluded.

This evidence review was informed by a TEC Assessment (2000), which was updated periodically through 2010. Subsequent evidence includes a number of RCTs, 2 of which included a sham control, and numerous RCTs that compared vertebroplasty with conservative management.

Review of Evidence
Systematic Reviews

Buchbinder et al (2018) published a Cochrane review of the literature up to November 2014. Studies compared vertebroplasty versus placebo (2 studies with 209 randomized participants), usual care (6 studies with 566 randomized participants), and kyphoplasty (4 studies with 545 randomized participants). The majority of participants were female, between 63.3 and 80 years of age, with symptom duration ranging from 1 week to more than 6 months. At 1 month, disease-specific quality of life measured by the QUALEFFO (a quality of life questionnaire in patients with vertebral fractures; scale 0 to 100, higher scores indicating worse quality of life) was 0.40 points worse in the vertebroplasty group. Based upon moderate quality evidence from 3 trials (1 placebo, 2 usual care, 281 participants) with up to 12 months follow-up, it is unclear if vertebroplasty increases the risk of new symptomatic vertebral fractures. Similarly, based upon moderate quality evidence from 2 placebo-controlled trials, it is unclear to what extent risk of other adverse events exists. There were 3/106 adverse events observed in the vertebroplasty group compared with 3/103 in the placebo group (risk ratio [RR], 1.01; 95% confidence interval [CI]: 0.21 to 4.85). Serious adverse events that have been reported with vertebroplasty included osteomyelitis, cord compression, thecal sac injury, and respiratory failure.

Staples et al (2011) conducted a patient-level meta-analysis of the 2 sham-controlled trials to determine whether vertebroplasty is more effective than sham in specific subsets of patients. This subset analysis focused on duration of pain (≤6 weeks vs. >6 weeks) and severity of pain (score <8 or ≥8 on an 11-point numeric rating scale). The analysis included 209 participants (78 from the Australian trial, 131 from the U.S. trial); 27% had pain of recent onset and 47% had severe pain at baseline. The primary outcome measures (pain scores and function on the Roland-Morris Disability Questionnaire at 1 month) did not differ significantly between groups. Responder analyses were also conducted based on a 3-unit improvement in pain scores, a 3-unit improvement in Roland-Morris Disability Questionnaire scores, and a 30% improvement in each of the pain and disability outcomes. The only difference observed between groups was a trend in the vertebroplasty group to achieve at least 30% improvement in pain scores (RR, 1.32; 95% CI, 0.98 to 1.76; p=.07), a result that may have been confounded by the greater use of opioid medications in that group.

Xie et al (2017), in a meta-analysis of RCTs, evaluated the efficacy and safety in percutaneous vertebroplasty and conservative treatment for patients with osteoporotic vertebral compression fractures. Thirteen studies were selected (N=1231 patients; 623 to vertebroplasty, 608 to conservative treatment). Outcomes included pain relief (from 1 week to 6 months), quality of life assessments, and the rate of adjacent-level vertebral fracture. Vertebroplasty was superior for pain relief at 1 week and at 1 month. It was inferior to conservative treatment for pain relief at 6 months. Vertebroplasty showed improvement over conservative treatment for quality of life, as measured using QUALEFFO. No statistically significant differences were found between treatments for the rate of adjacent-level vertebral fractures. Limitations included the inclusion of several studies with inadequate blinding and heterogenous reporting of patient characteristics outcomes.

Hinde et al (2020), in a meta-analysis of retrospective and prospective cohort studies, assessed the mortality outcomes of vertebral augmentation versus nonsurgical management in patients with
osteoporotic vertebral compression fractures.\textsuperscript{20} The meta-analysis included 7 studies (N=2,089,944; 382,070 treated with vertebral augmentation and 1,707,874 treated with nonsurgical management). Vertebral augmentation improved mortality compared with nonsurgical management at both 2- and 5-year follow-up. Limitations included heterogeneity in the number of enrolled patients in included studies as well as differences in health status.

Zhang et al (2020), in a meta-analysis of RCTs, assessed the efficacy of percutaneous vertebroplasty versus conservative treatment for patients with osteoporotic vertebral compression fractures.\textsuperscript{21} Ten studies were included, and outcomes consisted of pain relief at 1 week, 1 month, and 6 months; quality of life assessments; and the rate of new vertebral fractures. Compared with conservative treatment, percutaneous vertebroplasty was superior for pain relief at 1 week and 1 month, but not at 3 months. Results varied for quality of life assessments with similar outcomes between percutaneous vertebroplasty and conservative treatments on the Roland-Morris Disability Questionnaire. Limitations included an imbalance in baseline demographics and the clinical characteristics of patients in included studies.

Chang et al (2021), in a meta-analysis of RCTs and cohort studies, evaluated the effectiveness and safety of various interventions, including vertebroplasty versus kyphoplasty or conservative treatment, for treating osteoporotic vertebral compression fractures.\textsuperscript{22} Thirty-nine studies included vertebroplasty as a comparative arm. Outcomes included scores based on the visual analogue scale and Oswestry Disability Index. Vertebroplasty decreased scores on the visual analogue scale and Oswestry Disability Index compared with conservative treatment, but had similar outcomes compared with kyphoplasty. The rate of new fractures was similar for vertebroplasty versus conservative treatment and vertebroplasty versus kyphoplasty. Limitations consisted of the differences in indications, data types, follow-up times, and variables in included studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>Intervention</th>
<th>N (Range)</th>
<th>Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchbinder et al (2018)\textsuperscript{17}</td>
<td>2007-2016</td>
<td>21</td>
<td>Patients with osteoporotic vertebral fractures (mean age ranged from 63.3 to 80 years; symptom duration ranged from 1 week to &gt;6 months)</td>
<td>Vertebroplasty</td>
<td>2862 (46-404)</td>
<td>RCT</td>
</tr>
<tr>
<td>Staples et al (2011)\textsuperscript{18}</td>
<td>NR</td>
<td>2</td>
<td>Participants with 1-2 painful osteoporotic vertebral fractures &gt;12 months duration and unhealed, as confirmed by MRI, were randomly assigned to vertebroplasty or to a sham procedure.</td>
<td>Vertebroplasty vs. placebo (5 studies); kyphoplasty (7 studies); facet joint steroid injection (1)</td>
<td>209 (78-131)</td>
<td>RCT</td>
</tr>
<tr>
<td>Xie et al (2017)\textsuperscript{19}</td>
<td>NR-2017</td>
<td>13</td>
<td>Patients with OVCFs</td>
<td>PVP vs. conservative treatment</td>
<td>2561 (NR)</td>
<td>RCT</td>
</tr>
<tr>
<td>Hinde et al (2020)\textsuperscript{20}</td>
<td>NR-2018</td>
<td>7</td>
<td>Patients with OVCFs</td>
<td>Vertebral augmentation (vertebroplasty or balloon kyphoplasty) vs. nonsurgical management</td>
<td>2,089,944 (NR)</td>
<td>Retrospective and prospective cohort studies</td>
</tr>
<tr>
<td>Zhang et al (2020)\textsuperscript{21}</td>
<td>NR-2018</td>
<td>10</td>
<td>Patients with OVCFs</td>
<td>PVP vs. conservative treatment</td>
<td>NR</td>
<td>RCT</td>
</tr>
<tr>
<td>Chang et al (2021)\textsuperscript{22}</td>
<td>NR-2020</td>
<td>56</td>
<td>Patients with OVCFs</td>
<td>Vertebroplasty vs. conservative</td>
<td>6974 (14-191)</td>
<td>RCT, cohort studies</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
Percutaneous Vertebroplasty and Sacroplasty

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>Intervention</th>
<th>N (Range)</th>
<th>Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchbinder et al (2018)17</td>
<td></td>
<td></td>
<td></td>
<td>treatment (15 studies); kyphoplasty (24 studies)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo group at 1-month, score (n)</td>
<td></td>
<td></td>
<td></td>
<td>4.58 (71)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Vertebralplasty group at 1-month, score (n)</td>
<td></td>
<td></td>
<td></td>
<td>5.38 (71)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Absolute change between groups</td>
<td></td>
<td></td>
<td></td>
<td>0.4% worse (5% worse-5% better [n=71])</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Relative change between groups</td>
<td></td>
<td></td>
<td></td>
<td>0.7% worse (9% worse-8% better [n=71])</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Intervention group, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>28 (19.58)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Placebo group, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>19 (50.00)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>RR (CI)</td>
<td></td>
<td></td>
<td></td>
<td>1.47 (0.39 to 5.50)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td><strong>Duration of Pain</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staples et al (2011)18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean change score (SD) of pain, at 2 weeks, PVP vs. placebo</td>
<td></td>
<td></td>
<td></td>
<td>2.2 (2.8) vs. 2.5 (3.0)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Adjusted between group difference (CI) at 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td>-0.2 (-0.9 to 0.6)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Mean change score (SD) of pain, at 1 month, PVP vs. placebo</td>
<td></td>
<td></td>
<td></td>
<td>2.08 (3.0) vs. 2.2 (3.2)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Adjusted between group difference (CI) at 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td>0.6 (-0.2 to 1.4)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Xie et al (2017)18</td>
<td></td>
<td></td>
<td></td>
<td>N=1231</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>At 1-week (vertebroplasty superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>1.36 (0.55 to 2.17)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>At 1-month (vertebroplasty superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>1.56 (0.43 to 2.70)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>At 6-months (vertebroplasty inferior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>-1.59 (-2.9 to -0.27)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Total (vertebroplasty superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>-5.03 (7.94 to -2.12)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Hinde et al (2020)20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality, 2-year follow up, HR (CI), vertebral augmentation vs. nonsurgical management</td>
<td></td>
<td></td>
<td></td>
<td>0.70 (0.69 to 0.71)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Mortality, 5-year follow up, HR (CI), vertebral augmentation vs. nonsurgical management</td>
<td></td>
<td></td>
<td></td>
<td>0.79 (0.62 to 0.9999)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Zhang et al (2020)21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain relief at 1 week (PVP superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>1.67 (0.84 to 2.51)</td>
<td>p&lt;.0001</td>
<td></td>
</tr>
<tr>
<td>Pain relief at 1 month (PVP superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>1.98 (0.61 to 3.36)</td>
<td>p=.005</td>
<td></td>
</tr>
<tr>
<td>Pain relief at 3 months, MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>-0.44 (-2.03 to 1.15)</td>
<td>OR, 1.09</td>
<td>(0.72 to 1.64)</td>
</tr>
<tr>
<td>EuroQol questionnaire (PVP superior), MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>0.11 (0.01 to 0.20)</td>
<td>p=.03</td>
<td></td>
</tr>
<tr>
<td>Quality of Life Questionnaire of the European Foundation for Osteoporosis, MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>-7.29 (-12.60 to -1.99)</td>
<td>p&lt;.05</td>
<td></td>
</tr>
<tr>
<td>Roland–Morris Disability Questionnaire, MD (CI)</td>
<td></td>
<td></td>
<td></td>
<td>0.66 (-2.00 to 3.33)</td>
<td>OR, 1.09</td>
<td>(0.79 to 1.50)</td>
</tr>
<tr>
<td>Chang et al (2021)22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment effect for visual analogue scale, mean (CI), vertebroplasty vs. conservative treatment</td>
<td></td>
<td></td>
<td></td>
<td>-0.66 (-1.10 to -0.21)</td>
<td>OR, 1.09</td>
<td>(0.79 to 1.50)</td>
</tr>
<tr>
<td>Treatment effect for visual analogue scale, mean (CI), vertebroplasty vs. kyphoplasty</td>
<td></td>
<td></td>
<td></td>
<td>0.28 (-0.06 to 0.61)</td>
<td>OR, 0.99</td>
<td>(0.74 to 1.33)</td>
</tr>
<tr>
<td>Treatment effect for ODI, mean (CI), vertebroplasty vs. conservative treatment</td>
<td></td>
<td></td>
<td></td>
<td>-5.27 (-9.19 to -1.35)</td>
<td>OR, 1.09</td>
<td>(0.79 to 1.50)</td>
</tr>
</tbody>
</table>

NR: not reported; OVCF: osteoporotic vertebral compression fracture; PVP: percutaneous vertebroplasty; RCT: randomized controlled trial.

Table 2. Results of Systematic Reviews and Meta-Analyses on Percutaneous Vertebroplasty for Vertebral Compression Fractures of Between 6 Weeks and 1 Year Old
Percutaneous Vertebroplasty and Sacroplasty

Study Quality of Life New Fractures

| Treatment effect for ODI, mean (CI), vertebroplasty vs. kyphoplasty |
| 1.23 (-1.59 to 4.04) |

Study: 0.95% confidence interval; HR: hazard ratio; MD: mean difference; NR: not reported; ODI: Oswestry Disability Index; OR: odds ratio; PVP: percutaneous vertebroplasty; QUALEFFO: a quality of life questionnaire in patients with vertebral fractures; RR: relative risk; SD: standard deviation.

Randomized Controlled Trials

Vertebroplasty Versus Medical Management With Sham Controls

Three sham-controlled trials compared vertebroplasty with medical management using a sham control (that included local anesthetic), which mimicked the vertebroplasty procedure up to the point of cement injection. Buchbinder et al (2009) reported on results for a 4-center, randomized, double-blind, sham-controlled trial with 78 patients with 1 or 2 painful osteoporotic vertebral fractures with a duration of less than 1 year. Patients were assigned to vertebroplasty or sham procedure (ie, injection of local anesthetic into the facet capsule and/or periosteum). Ninety-one percent of participants completed 6 months of follow-up. The participants, investigators (other than the radiologists performing the procedure), and outcome assessors were blinded to the treatment assignment. Kroon et al (2014) reported results of the same trial at 12 and 24 months, maintaining blinding throughout the follow-up period. The primary outcome was overall pain measured on a visual analogue scale from 0 to 10, with 1.5 points representing the minimal clinically important difference. For the primary outcome, reviewers reported no significant differences in visual analogue scale pain score at 3, 12, or 24 months. With reductions in pain and improvements in quality of life observed in both groups, the authors concluded routine use of vertebroplasty provided no benefit.

Kallmes et al (2009) conducted a multicenter, randomized, double-blind, sham-controlled, investigational vertebroplasty safety and efficacy trial in which 131 participants with 1 to 3 painful osteoporotic vertebral fractures were assigned to vertebroplasty or sham procedure (injection of local anesthetic into the facet capsule and/or periosteum). Participants had back pain for no more than 12 months and had a current pain rating of at least 3 on visual analogue scale at baseline. Participants were evaluated at various time points to 1 year postprocedure. Ninety-seven percent completed a 1-month follow-up; 95% completed 3 months. The primary outcomes were Roland-Morris Disability Questionnaire scores and average back pain intensity during the preceding 24 hours at 1 month, with a reduction of 30% in Roland-Morris Disability Questionnaire and visual analogue scale pain scores considered a clinically meaningful difference.

For the primary endpoints at 1 month, there were no significant between-group differences. There was a trend toward a higher clinically meaningful improvement in pain at 1 month (30% reduction from baseline) in the vertebroplasty group (64% vs. 48%, respectively; p= .06). At 3 months, 51% from the control group and 13% in the vertebroplasty group crossed over (p<.001). Comstock et al (2013) reported on patient outcomes at 1 year, at which point 16% of patients who underwent vertebroplasty and 60% of control subjects had crossed over to the alternative procedure (p<.001). The as-treated analysis found no significant difference in Roland-Morris Disability Questionnaire or pain scores between the 2 groups. Intention-to-treat analysis found a modest 1-point difference in pain rating and no significant difference in Roland-Morris Disability Questionnaire score. There was a significant difference in the percentage of patients showing a 30% or greater improvement in pain (70% of patients randomized to vertebroplasty vs. 45% of patients randomized to the control group). One limitation of this study is that at 14 days, 63% of patients in the control group correctly guessed they had the control intervention, and 51% of patients in the vertebroplasty group correctly guessed they had the vertebroplasty.

Firanescu et al (2018) published the results of a randomized, double-blind, sham-controlled clinical trial performed in 4 community hospitals in the Netherlands from 2011 to 2015. The main outcome measured was mean reduction in visual analogue scale scores at 1 day, 1 week, and 1, 3, 6, and 12 months. The mean reduction in visual analogue scale score was statistically significant in the...
vertebroplasty and sham procedure groups at all follow-up points after the procedure compared with baseline. These changes in visual analogue scale scores were not statistically significant between the groups during 12 months of follow-up.

Table 3. Summary of Characteristics of Key RCT Comparing Vertebroplasty Versus Medical Management With Sham Controls

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants (N)</th>
<th>Interventions</th>
</tr>
</thead>
</table>

OVCF: osteoporotic vertebral compression fracture; RCT: randomized controlled trial; VAS: visual analogue scale.
\(^1\) Injection of local anesthetic into the facet capsule and/or periosteum.

Table 4. Summary of Results of Key RCT Comparing Vertebroplasty Versus Medical Management with Sham Controls

<table>
<thead>
<tr>
<th>Study</th>
<th>VAS</th>
<th>RMDQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchbinder et al (2009)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 14 Mean difference between groups (CI)</td>
<td>0.1 (-0.8-1.1)</td>
<td>-0.6 (-2.4-1.2)</td>
</tr>
<tr>
<td>p-value</td>
<td>.77</td>
<td>35</td>
</tr>
<tr>
<td>Month 1 Mean difference between groups (CI)</td>
<td>0.7 (-0.3-1.70)</td>
<td>0.7 (-1.3-2.8)</td>
</tr>
<tr>
<td>p-value</td>
<td>.19</td>
<td>49</td>
</tr>
<tr>
<td>Kallmes et al (2009)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1 Mean difference between groups (CI)</td>
<td>-0.43 (-1.17-0.31)</td>
<td>-0.11 (-0.85-0.63)</td>
</tr>
<tr>
<td>Week 1 Mean difference between groups (CI)</td>
<td>0.41 (-0.33-1.15)</td>
<td>0.21 (-0.54-0.96)</td>
</tr>
<tr>
<td>Month 3 Mean difference between groups (CI)</td>
<td>0.39 (-0.33-1.15)</td>
<td>0.45 (-0.37-1.24)</td>
</tr>
<tr>
<td>Month 12 Mean difference between groups (CI)</td>
<td>-0.43 (-1.17-0.31)</td>
<td>-0.11 (-0.85-0.63)</td>
</tr>
<tr>
<td>Day 1 Mean difference between groups (CI)</td>
<td>-0.43 (-1.17-0.31)</td>
<td>-0.11 (-0.85-0.63)</td>
</tr>
<tr>
<td>Week 1 Mean difference between groups (CI)</td>
<td>0.41 (-0.33-1.15)</td>
<td>0.21 (-0.54-0.96)</td>
</tr>
<tr>
<td>Month 3 Mean difference between groups (CI)</td>
<td>0.39 (-0.33-1.15)</td>
<td>0.45 (-0.37-1.24)</td>
</tr>
<tr>
<td>Month 12 Mean difference between groups (CI)</td>
<td>-0.43 (-1.17-0.31)</td>
<td>-0.11 (-0.85-0.63)</td>
</tr>
</tbody>
</table>

CI: 95% confidence interval; NR: not reported; RCT: randomized controlled trial; RMDQ: Roland-Morris Disability Questionnaire; SD: standard deviation; VAS: visual analogue scale.

Table 5. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchbinder et al (2009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallmes et al (2009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Firanescu et al (2018)</td>
<td>2. Lack of screening for co-occurring pain conditions.</td>
<td>3. No reporting of harms.</td>
<td>5. Investigator modified pain window from 6 to 9 weeks.</td>
<td>5. Investigator modified pain window from 6 to 9 weeks.</td>
<td></td>
</tr>
</tbody>
</table>
MRI: magnetic resonance imaging

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<table>
<thead>
<tr>
<th>Study</th>
<th>Population&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Intervention&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Comparator&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Outcomes&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Follow-up&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2. MRI was not conducted.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Blinding&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Selective Reporting&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Follow-Up&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Power&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Statistical&lt;sup&gt;f&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchbinder et al (2009)</td>
<td></td>
<td></td>
<td>2. 30% of eligible participants declined to participate, selection bias cannot be ruled out.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallmes et al (2009)</td>
<td>1. At 14 days, &gt; 50% of participants in either arm correctly identified their intervention assignment.</td>
<td></td>
<td>4. Due to high crossover the group differences in outcomes were complicated.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vertebroplasty Versus Medical Management Without Sham Controls

Chen et al (2014) reported on a nonblinded RCT comparing vertebroplasty with conservative management. The trial included 89 patients with chronic compression fractures confirmed by magnetic resonance imaging and persistent severe pain for 3 months or longer. The evaluation was...
percutaneous vertebroplasty and sacroplasty
Page 12 of 30

performed at 1 week and 1, 3, 6, and 12 months. Over the course of 1 year, pain scores decreased from 6.5 to 2.5 in the vertebroplasty group and from 6.4 to 4.1 in the control group (p<.001). Complete pain relief was reported by 84.8% of patients in the vertebroplasty group and 34.9% of controls. The final Oswestry Disability Index score was 15.0 in the vertebroplasty group and 32.1 in the conservative management group (p<.001), and the final Roland-Morris Disability Questionnaire score was 8.1 for vertebroplasty and 10.7 for controls (p<.001).

Farrokhi et al (2011) reported on a blinded RCT that compared vertebroplasty with optimal medical management in 82 patients.30. Patients had painful osteoporotic vertebral compression fractures that were refractory to analgesic therapy for at least 4 weeks and less than 1 year. Control of pain and improvement in quality of life were measured by independent raters before treatment and at 1 week and 2, 6, 12, 24, and 36 months after treatment began. Radiologic evaluation to measure vertebral body height and correction of deformity was performed before and after treatment and after 36 months of follow-up. Adverse events include new symptomatic adjacent fractures in 1 patient in the treatment group and 6 in the control group. Additionally, 1 patient experienced epidural cement leakage, which caused severe lower extremity pain and weakness, and had to be treated with bilateral laminectomy and evacuation of the bone cement.

Table 7. Summary of Key RCT Characteristics - Vertebroplasty Versus Medical Management
<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants (N)</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al (2014)29,</td>
<td>China</td>
<td>1</td>
<td>2007-2012</td>
<td>Patients with chronic compression fractures confirmed by MRI and persistent severe pain for &lt;3 months (89)</td>
<td>Active Vertebroplasty  Comparator Conservative Management</td>
</tr>
<tr>
<td>Farrokhi et al (2011)30,</td>
<td>Iran</td>
<td>1</td>
<td>2004-2005</td>
<td>Patients with painful osteoporotic vertebral compression fractures refractory to analgesic therapy for &gt;4 months, but &lt;1 year (82)</td>
<td>Vertebroplasty  Optimal Medical Management</td>
</tr>
</tbody>
</table>

MRI: magnetic resonance imaging; RCT: randomized controlled trial.

Table 8. Summary of Key RCT Results
<table>
<thead>
<tr>
<th>Study</th>
<th>Pain Score Mean difference between groups (CI); p-value</th>
<th>ODI score</th>
<th>RMDQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al (2014) (N=89)29, Intervention Group, Pooled at 1-year</td>
<td>2.5 (-3.72 to -2.28); &lt;.001</td>
<td>15.0</td>
<td>8.1</td>
</tr>
<tr>
<td>Chen et al (2014) (N=89)29, Control Group, Pooled at 1-year</td>
<td>4.1 (-15.00 to -12.82); &lt;.001</td>
<td>32.1</td>
<td>10.7</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Farrokhi et al (2011)30, Week 1</td>
<td>Mean difference between groups (CI); p-value</td>
<td>-3.1 (-3.72 to -2.28); &lt;.001</td>
<td>-14.0 (-15.00 to -12.82); &lt;.028</td>
</tr>
<tr>
<td>Month 2 Mean difference between groups (CI); p-value</td>
<td>-2.9 (-4.9 to -0.82); &lt;.011</td>
<td>-15.0 (-16.76 to -13.24); &lt;.019</td>
<td></td>
</tr>
</tbody>
</table>
Study | Pain Score | ODI score | RMDQ |
--- | --- | --- | --- |
Month 6 Mean difference between groups (CI); p-value | -1.9 (-3.25 to -0.55); <.021 | -11.0 (-12.17 to -7.83); <.011 |
Month 12 Mean difference between groups (CI); p-value | -1.9 (-2.9 to 0.9); <.11 | -12.0 (-13.5 to -11.5); <.021 |

CI: confidence interval; ODI: Oswestry Disability Index; RCT: randomized controlled trial; RMDQ: Roland-Morris Disability Questionnaire; VAS: visual analogue scale.

Table 9. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al (2014)29.</td>
<td></td>
<td></td>
<td>3. Investigator modified duration of the conservative therapy from 6 to 4 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.


Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 10. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Follow-Up</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al (2014)29.</td>
<td></td>
<td>1,2. This study was not blinded.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.


Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Nonrandomized Comparative Studies

Edidin et al (2011, 2015) reported on mortality risk rates in Medicare patients who had vertebral compression fractures and were treated with vertebroplasty, kyphoplasty, or
nonoperatively. These studies were industry funded. In the 2015 report, they identified 1,038,956 patients who had vertebral compression fractures between 2005 and 2009. The dataset included 141,343 kyphoplasty patients and 75,364 vertebroplasty patients. The matched cohort included 100,649 nonoperated patients, 36,657 kyphoplasty patients, and 24,313 vertebroplasty patients. Survival was calculated from the index diagnosis date until death or the end of follow-up (up to 4 years). Analysis of the whole data set before matching indicated that patients in the nonoperated cohort had a 55% (95% CI, 53% to 56%; p<.001) higher risk of mortality than the kyphoplasty cohort and a 25% (95% CI, 23% to 26%; p<.001) higher mortality risk than the vertebroplasty cohort. After propensity matching, the risk of mortality at 4 years was 47.2% in the nonoperated group compared with 42.3% in the kyphoplasty group (p<.001) and 46.2% in the vertebroplasty group (p<.001).

Lin et al (2017) reported on mortality risk in elderly patients (>70 years old) who had vertebral compression fractures and were treated with early vertebroplasty (within 3 months) or conservative therapy. The data set consisted of 10,785 Taiwanese patients who were selected through the National Health Insurance Research Database, of whom 1773 patients received vertebroplasty, and 5324 did not; a minority of these patients had osteoarthritis. The authors found that a “significant difference in survival curves of mortality and respiratory failure” existed between both groups of patients (p<.05). The incidence of death at 1 year in the vertebroplasty group was 0.46 per 100 person-months (95% CI, 0.38 to 0.56). The incidence of death at 1 year in the nonvertebroplasty group was 0.63 per 100 person-months (95% CI, 0.57 to 0.70). With regard to respiratory failure, hazard ratio (HR) between groups was 1.46 (95% CI, 1.04 to 2.05; p=.028). Limitations of this study included the broad selection of the population, which was not restricted only to patients with osteoporotic lesions. Also, authors were limited by the database, which did not report on pain or functional outcomes.

Section Summary: Percutaneous Vertebroplasty for Vertebral Compression Fractures of Between 6 Weeks and 1 Year Old
Despite evidence from numerous RCTs, including several with sham controls, the efficacy of vertebroplasty for painful osteoporotic compression fractures of less than 1 year remains uncertain. Six meta-analysis studies have been published, but all of them have numerous limitations due to heterogeneity of included studies. Another major limitation to several meta-analyses is that they do not specify the timeframe for osteoporotic vertebral compression fractures. There remains some uncertainty related to the interpretation of these conclusions. While the use of a sham procedure is a major methodologic strength to control for nonspecific (placebo) effects, the sham used is controversial, given that the effect of injecting local anesthetic in the facet capsule and/or periosteum is unknown. Also, the appropriateness of outcome measures used to detect clinically meaningful differences in pain might not have been optimal, because the studies were underpowered to detect differences in clinical response rates. Questions have also been raised about the low percentage of patients screened who participated in the trial, the volume of polymethylmethacrylate injected, and the inclusion of patients with chronic pain.

Percutaneous Vertebroplasty for Vertebral Compression Fractures of Less Than 6 Weeks Old
Clinical Context and Therapy Purpose
The purpose of vertebroplasty is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as conservative management, in individuals with symptomatic osteoporotic vertebral fractures less than 6 weeks old. The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals with symptomatic osteoporotic vertebral fractures less than 6 weeks old. With acute fractures, these individuals experience severe pain, decreased ambulatory function, and a lessened response to conservative medical management.
Interventions
The therapy being considered is vertebroplasty.

Comparators
Comparators of interest include conservative management. A detailed review of the comparators is listed in the above indication.

Outcomes
The general outcomes of interest are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Symptoms can include back pain and demonstrated fracture on radiography. The most current research available tracks follow-up to 12 months or more. A number of studies have longer term follow-up at more than 5 years, which is ideal for understanding all of the outcomes, particularly the occurrence of new vertebral compression fractures after vertebroplasty.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:
1. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
2. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
3. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
4. Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Randomized Controlled Trials
Vertebroplasty Versus Medical Management With Sham Controls
Clark et al (2016) reported on results from the Safety and Efficacy of Vertebroplasty of Acute Painful Osteoporotic Fractures (VAPOUR) trial (see Table 11).34, VAPOUR was a multicenter, double-blind trial of vertebroplasty in 120 patients with vertebral fractures of less than 6 weeks in duration and back pain of at least 7 out of 10 on a numeric rating scale. This trial followed a similar protocol as that used in the Kallmes et al (2009) trial (discussed above). The primary outcome (the percentage of patients with a numeric rating scale score <4 out of 10 at 14 days postprocedure) was met in a greater percentage of patients in the vertebroplasty group (44%) than in the sham control group (21%). This between-group difference was maintained through 6 months.

Other outcome measures were significantly improved in the vertebroplasty group at 1 or both of the time points (see Table 12). The benefit of vertebroplasty was found predominantly in the thoracolumbar subgroup, with 48% (95% CI, 27% to 68%) more patients meeting the primary endpoint (61% in the vertebroplasty group vs. 13% in the control group). The investigators commented that the thoracolumbar junction is subject to increased dynamic load, and fractures at this junction have the highest incidence of mobility. No benefit from vertebroplasty was found in the non-thoracolumbar subgroup. Postprocedural hospital stay was reduced from a mean of 14 days in the control group to 8.5 days after vertebroplasty, even though physicians who determined the discharge date remained blinded to treatment. In the vertebroplasty group, there were 2 serious adverse events due to sedation and transfer to the radiology table. In the control group, 2 patients developed spinal cord compression; 1 underwent decompressive surgery and the other, not a surgical candidate, became paraplegic.

Vertebroplasty Versus Medical Management Without Sham Controls
Klazen et al (2010) reported on the vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures, an open-label randomized trial of 202 patients at 6 hospitals in the Netherlands and Belgium.35 Of 431 patients eligible for randomization, 229 (53%) had
spontaneous pain relief during assessment. Participants with at least 1 painful osteoporotic vertebral fracture of 6 weeks or less in duration were assigned to vertebroplasty or conservative management. The primary outcome was pain relief of 3 points measured on a 10-point visual analogue scale at 1 month and 1 year.

A total of 101 subjects were enrolled in the treatment group and the control arm; 81% completed 12-month follow-up. There were no significant differences in the primary outcome (pain relief of 3 points) measured at 1 month and 1 year. Vertebroplasty resulted in greater pain relief than did medical management through 12 months (p<.001); there were significant between-group differences in mean visual analogue scale scores at 1 month or at 1 year. Survival analysis showed significant pain relief was quicker (29.7 days vs. 115.6 days) and was achieved by more patients after vertebroplasty than after conservative management.

Yi et al (2014) assessed the occurrence of new vertebral compression fractures after treatment with cement augmenting procedures (vertebroplasty or kyphoplasty) versus conservative treatment in an RCT with 290 patients (363 affected vertebrae).36 Patients treated conservatively had a mean length of stay of 13.7 days. Return to usual activity occurred at 1 week for 87.6% of operatively treated patients and 2 months for 59.2% of conservatively treated patients. All patients were evaluated with radiographs and magnetic resonance imaging at 6 months and then at yearly intervals until the last follow-up session. At a mean follow-up of 49.4 months (range, 36–80 months), 10.7% of patients had experienced 42 new symptomatic vertebral compression fractures. There was no significant difference in the incidence of new vertebral fractures between the operative (18 total; 9 adjacent, 9 nonadjacent) and conservative (24 total; 5 adjacent, 16 nonadjacent, 3 same level) groups but the mean time to a new fracture was significantly shorter in the operative group (9.7 months) than in the nonoperative group (22.4 months).

Leali et al (2016) published a brief report on a multicenter RCT enrolling 400 patients with osteoporotic thoracic or lumbar vertebral compression fractures who were treated with vertebroplasty or conservative therapy.37 Fractures were treated within 2 weeks of pain onset. Details of randomization and rates of follow-up were not reported. At 1 day after treatment, the vertebroplasty group had a reduction in pain scores and improvement in physical function, with visual analogue scale pain scores decreasing from 4.8 (maximum, 5.0) to 2.3 (p=.023) and Oswestry Disability Index scores improving from 53.6% to 31.7% (p=.012). Sixty-five percent of patients treated with vertebroplasty had stopped all analgesic use within 48 hours. The conservatively managed group showed no benefit in the first 48 hours, but by 6 weeks visual analogue scale and Oswestry Disability Index scores were described as similar in both groups (specific data not reported). Evaluation of this trial was limited by incomplete reporting.

Yang et al (2016) compared vertebroplasty with conservative therapy in 135 patients over 70 years of age with severe back pain due to an osteoporotic vertebral fracture after minor or mild trauma.38 Vertebroplasty was performed at a mean of 8.4 days after pain onset. Patients in the conservative therapy group were placed on bed rest and analgesics for at least 2 weeks after diagnosis, followed by bracing and assistive devices. All patients receiving vertebroplasty could stand and walk with a brace at 1 day posttreatment, while only 12 (23.5%) patients in the control group could stand up and walk after 2 weeks of bed rest. The average duration of bed rest from pain onset was 7.8 days (range, 2–15 days) in the vertebroplasty group compared with 32.5 days (range, 14–60 days) in the conservative therapy group. At 1-year follow-up, there was a similar percentage of additional compression fractures but a significantly higher complication rate in the conservative therapy group (35.3%) than in the vertebroplasty group (16.1%; p<.001). Complications included pneumonia, urinary tract infection, deep vein thrombosis, depression, and sleep disorders.

Table 11. Summary of Key RCT Characteristics Involving Vertebroplasty Versus Medical Management without Sham Controls
**Study; Countries; Sites; Dates; Participants (N); Interventions**

<table>
<thead>
<tr>
<th>Study; <strong>Trial</strong></th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants (N)</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klazen et al (2010)&lt;sup&gt;35&lt;/sup&gt;</td>
<td>EU</td>
<td>6</td>
<td>2005-2008</td>
<td>Patients &gt;50 years with radiographically confirmed VCF, back pain for &lt;6 weeks, VAS &gt;5</td>
<td>Vertebroplasty (101)</td>
</tr>
<tr>
<td>Yi et al (2014)&lt;sup&gt;36&lt;/sup&gt;</td>
<td>China</td>
<td>1</td>
<td>2005-2009</td>
<td>Patients with OVC F</td>
<td>PVP or PKP (169)</td>
</tr>
<tr>
<td>Leali et al (2010)&lt;sup&gt;37&lt;/sup&gt;</td>
<td>International</td>
<td>4</td>
<td>NR</td>
<td>Post-menopausal women with 1 thoracic or lumbar symptomatic OVCF caused by primary or secondary osteoporosis.</td>
<td>PVP including analgesic and osteoporosis medication (200)</td>
</tr>
<tr>
<td>Yang et al (2015)&lt;sup&gt;38&lt;/sup&gt;</td>
<td>China</td>
<td>1</td>
<td>2009-2011</td>
<td>Patients &gt;70 years with acute OVCF, severe pain from minor or mild trauma</td>
<td>PVP (56 at 1 y)</td>
</tr>
</tbody>
</table>

NR: not reported; OVC: osteoporotic vertebral compression fractures; PKP: percutaneous kyphoplasty; PVP: percutaneous vertebroplasty; RCT: randomized controlled trial; VCF: vertebral compression fracture; VAS: visual analogue scale.

**Table 12. Summary of Key RCT Results Involving Vertebroplasty Versus Medical Management without Sham Controls**

<table>
<thead>
<tr>
<th>Study</th>
<th>VAS</th>
<th>Quality of Life</th>
<th>Refracture Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klazen et al (2010)&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Mean difference between groups in reduction of mean VAS score from baseline</td>
<td>RMDQ&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Median follow-up of 12.0 months (range: 1-24)</td>
</tr>
<tr>
<td>Month 1 (CI)</td>
<td>2.0 (1.13-2.80)</td>
<td>PVP: 12.5</td>
<td>PVP: 18 (16.48%)</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;.0001</td>
<td>Control: 13.5</td>
<td>Control: 30 (24.71%)</td>
</tr>
<tr>
<td>Month 12 (CI)</td>
<td>2.0 (1.13-2.80)</td>
<td>PVP: 9</td>
<td>PVP: 9</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;.0001</td>
<td>Control: 12</td>
<td>Control: 12</td>
</tr>
<tr>
<td>Yi et al (2014)&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Month 12 (%)</td>
<td>-</td>
<td>PVP/PKP: 18 (8.28%)</td>
</tr>
<tr>
<td>Intervention</td>
<td>-</td>
<td>-</td>
<td>Control: 24 (19.83%)</td>
</tr>
<tr>
<td>Control</td>
<td>-</td>
<td>-</td>
<td>Time interval of recompression</td>
</tr>
<tr>
<td>p-value</td>
<td>≤.023</td>
<td>≤.012</td>
<td>9.7 ± 17.8 months</td>
</tr>
<tr>
<td>Leali et al (2016)&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Intervention 24 hours after surgery, mean</td>
<td>ODI, %</td>
<td>22.4 ± 7.99 months</td>
</tr>
<tr>
<td>p-value</td>
<td>≤.023</td>
<td>≤.012</td>
<td>.017</td>
</tr>
<tr>
<td>Yang et al (2015)&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Analysis of variance models, Month 1 (SD)</td>
<td>PVP: 2.4±1</td>
<td>PVP: 48±10</td>
</tr>
<tr>
<td>Control: 4.8±1</td>
<td>Control: 71±7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analysis of variance models, Month 12 (SD)</td>
<td>PVP: 1.8±0.3</td>
<td>PVP: 30±5</td>
<td></td>
</tr>
<tr>
<td>Control: 3±0.5</td>
<td>Control: -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>≤.012</td>
<td>≤.001</td>
<td>PVP: 5 (8.9%); &lt;.0001</td>
</tr>
</tbody>
</table>

CI: 95% confidence interval; ODI: Oswestry Disability Index; PKP: percutaneous kyphoplasty; PVP: percutaneous vertebroplasty; RCT: randomized controlled trials; RMDQ: Roland-Morris Disability Questionnaire; VAS: visual analogue scale; SD: standard deviation.

<sup>1</sup>The RMDQ results from the Klazen paper are based on estimates due to the graphical presentation of the results, rather than the reporting of the numerical values.

<sup>2</sup>The results from the Yang paper are based on estimates due to the graphical presentation of the results; numerical results not reported.
### Table 13. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population*</th>
<th>Interventionb</th>
<th>Comparatorc</th>
<th>Outcomesd</th>
<th>Follow-Up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klazen et al (2010)</td>
<td>35, None reported</td>
<td>4. Selection criteria for PVP or PKP unclear, some patients had &gt; fracture</td>
<td>3. None reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yi et al (2014)</td>
<td>36, 4. Selection criteria for PVP or PKP unclear, some patients had &gt; fracture</td>
<td>1. Limited to post-menopausal women</td>
<td>1,2 Follow-up period limited to &lt; 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leali et al (2010)</td>
<td>37, 1. Limited to post-menopausal women</td>
<td>4. Study population limited to &gt; 70 years of age at single spine center</td>
<td>1,2 Follow-up period limited to &lt; 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al (2015)</td>
<td>38, 4. Study population limited to &gt; 70 years of age at single spine center</td>
<td>3. Study population limited to &gt; 70 years of age at single spine center</td>
<td>3. None reported</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PKP: percutaneous kyphoplasty; PVP: percutaneous vertebroplasty; The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

*Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

*Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

*Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.


*Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other

### Table 14. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocationa</th>
<th>Blindingb</th>
<th>Selective Reportingc</th>
<th>Follow-Upd</th>
<th>Power*</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klazen et al (2010)</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
</tr>
<tr>
<td>Yi et al (2014)</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
<td>1,2, No masking</td>
</tr>
<tr>
<td>Leali et al (2010)</td>
<td>1,2,3, unclear if masking occurred</td>
<td>1,2,3, unclear if masking occurred</td>
<td>1,2,3, unclear if masking occurred</td>
<td>1,2,3, unclear if masking occurred</td>
<td>1,2,3, unclear if masking occurred</td>
<td>1,2,3, unclear if masking occurred</td>
</tr>
<tr>
<td>Yang et al (2015)</td>
<td>1,2,3 No masking</td>
<td>1,2,3 No masking</td>
<td>1,2,3 No masking</td>
<td>1,2,3 No masking</td>
<td>1,2,3 No masking</td>
<td>1,2,3 No masking</td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.


*Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

*Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based
on clinically important difference.

' Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Section Summary: Percutaneous Vertebroplasty for Vertebral Compression Fractures of Less Than 6 Weeks Old

In a sham-controlled randomized trial, where no anesthetic was injected into the periosteum, there was a significant benefit of vertebroplasty in patients who had severe pain of fewer than 6 weeks in duration following vertebral fracture at the thoracolumbar junction. Other RCTs without sham controls have reported that vertebroplasty is associated with significant improvements in pain, earlier improvements in function, and reductions in the duration of bed rest compared with conservatively managed patients.

Percutaneous Sacroplasty

Clinical Context and Therapy Purpose

Sacral insufficiency fractures are the consequence of stress on weakened bone and often cause low back pain in the elderly population.1 Osteoporosis is the most common risk factor for sacral insufficiency fractures. Lourie (1982) described spontaneous fracture of the sacrum in individuals with osteoporosis as presenting as lower back and buttock pain with or without referred pain in the legs.39 Although common, sacral insufficiency fractures can escape detection due to low provider suspicion and poor sensitivity on plain radiographs, slowing the application of appropriate intervention.

The purpose of sacroplasty is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as conservative management, in individuals with sacral insufficiency fractures.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with sacral insufficiency fractures. Sacral insufficiency fractures are a stress fracture, resulting from a regular stress applied to a bone with reduced elasticity. Often, these fractures are associated with underlying metabolic bone disease condition like osteoporosis. Examples of risk factors include corticosteroid therapy use, female sex, pelvic radiation, rheumatoid arthritis, and hyperparathyroidism.

Interventions

The therapy being considered is sacroplasty, a minimally invasive procedure for treating pathological fractures of the sacral vertebral body or sacral ala. The procedure involves percutaneous insertion of 1 or more bone needles into the sacrum and injection of bone cement under fluoroscopy and/or computed tomography visual guidance.

Comparators

Comparators of interest include conservative management. Conservative management includes physical therapy, analgesics, narcotics, and hormone treatments. Examples of conservative management for sacral insufficiency fractures are varied and can include bed rest and pain medication to early physical therapy.

Outcomes

The general outcomes of interest are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Possible negative outcomes include complications with sedation, cement leakage into the presacral space, spinal canal, sacral foramen, or sacroiliac
joint, and possible spinal compression due to extravasation of cement. At least 1 year of follow-up is desirable to adequately evaluate outcomes.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

1. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
2. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
3. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
4. Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Observational Studies**

Sacroplasty is an evolving technique achieved using numerous methods (short-axis, long-axis, balloon-assisted short-axis, iliosacral screws). No randomized trials of sacroplasty were identified. Frey et al (2008) conducted the largest prospective observational cohort study, assessing 52 consecutive patients undergoing sacroplasty for sacral insufficiency fractures using the short-axis technique. Patients had a mean age of 75.9 years, mean duration of symptoms of 34.5 days (range, 4-89 days), and mean visual analogue scale score of 8.1 at baseline. Improvements in visual analogue scale scores were measured at 30 minutes and 2, 4, 12, 24, and 52 weeks postprocedure. At each interval, statistically significant improvements over baseline were observed and maintained through 52 weeks.

Kortman et al (2013) reported on the largest series, a retrospective multicenter analysis. They evaluated 204 patients with painful sacral insufficiency fractures and 39 patients with symptomatic sacral lesions treated with the short-axis or long-axis technique. One hundred sixty-nine patients had bilateral sacral insufficiency fractures, and 65 patients had additional fractures of the axial skeleton. Visual analogue scale scores improved from 9.2 before treatment to 1.9 after treatment in patients with sacral insufficiency fractures and from 9.0 to 2.6 in patients with sacral lesions. There was 1 case of radicular pain due to extravasation of cement requiring surgical decompression.

Frey et al (2017) reported on patients treated with percutaneous sacroplasty, particularly the long-term efficacy of sacroplasty versus nonsurgical management. This prospective, observational cohort study spanned 10 years and comprised 240 patients with sacral insufficiency fractures. Thirty-four patients were treated with nonsurgical methods, and 210 patients were treated with sacroplasty. Pain, as measured by visual analogue scale, was recorded before treatment and at several follow-ups. Mean pretreatment visual analogue scale for the sacroplasty group was 8.29; for the nonsurgical treatment group, it was 7.47. Both forms of treatment resulted in significant visual analogue scale improvement from pretreatment to the 2-year follow-up (p<.001). However, the sacroplasty treatment group experienced significant visual analogue scale score improvement consistently at many of the follow-up points (pretreatment to post [p<.001]; posttreatment through 2 weeks [p>.001]; 12 weeks through 24 weeks [p=.014]; 24 weeks through 1 year [p=.002]). Meanwhile, the group with nonsurgical treatment only experienced 1 significant pain improvement score, which was at the 2-week follow-up posttreatment (p=.002). One major limitation of this study was that the nonsurgical treatment group was not followed up at the 10-year mark whereas the sacroplasty group did receive follow-up.

There are several retrospective reviews with roughly 50 patients per publication. One reported by Dougherty et al (2014) described a series of 57 patients treated with sacroplasty for sacral insufficiency fractures. The short- or the long-axis approach was dictated by the length and type of the fracture and patient anatomy. Follow-up data at 2.5 weeks were available for 45 (79%) patients, and the outcome measures were inconsistent. For example, activity pain scores were collected from
13 patients, and rest pain scores were collected from 29 patients. Of the 45 patients with outcomes data, 37 (82%) had experienced a numeric or descriptive decrease from initial pain of at least 30%.

**Adverse Events**
There are complications related to cement leakage with sacroplasty that are not observed with vertebroplasty. Leakage of polymethylmethacrylate into the presacral space, spinal canal, sacral foramen, or sacroiliac joint may result in pelvic injection of polymethylmethacrylate, sacral nerve root or sacral spinal canal compromise, or sacroiliac joint dysfunction.44, Performing sacroplasty only on zone 1 fractures can minimize these risks.45,

**Section Summary: Percutaneous Sacroplasty**
No RCTs evaluating percutaneous sacroplasty for sacral insufficiency were identified. The available evidence includes 2 prospective cohort studies and several retrospective series. These studies have reported rapid and sustained decreases in pain following percutaneous sacroplasty. Additional reports are mostly consistent in reporting immediate improvement following the procedure. Due to the limited number of patients and the retrospective nature of the evidence base, harms associated with sacroplasty have not been adequately studied. The small numbers of treated patients leave uncertainty regarding the impact of sacroplasty on health outcomes.

**Supplemental Information**
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

**2014 Input**
In response to requests, input was received from 2 physician specialty societies and 3 academic medical centers while this policy was under review in 2014. Input was sought on the treatment of acute vertebral fractures when there is severe pain that has led to hospitalization or persists at a level that prevents ambulation, and on the treatment of traumatic fractures that have remained symptomatic after 6 weeks of conservative treatment. Input on these issues was mixed.

**2008 Input**
In response to requests, input was received from 5 physician specialty societies and 2 academic medical centers while this policy was under review in 2008. Unsolicited input was received from a sixth physician specialty society. All reviewers disagreed with the proposed policy and provided references in support of the use of vertebroplasty. Vertebroplasty has been investigated as an intervention to provide mechanical support and symptomatic relief in patients with an osteoporotic vertebral compression fracture and in those with osteolytic lesions of the spine (ie, multiple myeloma, metastatic malignancies). Clinical input obtained in 2008 provided uniform support for the use of vertebroplasty in painful osteoporotic fractures. Reconsideration of the available evidence (consistent results of numerous case series, including large prospective reports) and evaluation of the input led to a conclusion that the evidence was sufficient to determine that vertebroplasty is a reasonable treatment option in patients with vertebral fractures who have failed to respond to conservative treatment (at least 6 weeks with analgesics, physical therapy, and rest). It is also clinically reasonable to consider the evidence supporting the clinical benefit of vertebroplasty in the osteoporotic vertebral fracture to support its use in osteolytic lesions of the spine (e.g., multiple myeloma, metastatic malignancies).

**Practice Guidelines and Position Statements**
Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**American College of Radiology**

In 2022, the American College of Radiology (ACR) revised its Appropriateness Criteria for the use of percutaneous vertebral augmentation in the management of vertebral compression fractures.46] Table 15 shows the appropriateness categories for each variant.

**Table 15. ACR Appropriateness Criteria for the Use of Percutaneous Vertebral Augmentation for the Management of Vertebral Compression Fractures**

<table>
<thead>
<tr>
<th>Variants</th>
<th>Appropriateness Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Asymptomatic, osteoporotic VCF. Initial treatment&quot;</td>
<td>Usually Not Appropriate</td>
</tr>
<tr>
<td>&quot;Symptomatic osteoporotic VCF with bone marrow edema or intravertebral cleft. Initial treatment&quot;</td>
<td>Usually Appropriate</td>
</tr>
<tr>
<td>&quot;New symptomatic VCF. History of prior vertebroplasty or surgery. Initial treatment.&quot;</td>
<td>Usually Appropriate</td>
</tr>
<tr>
<td>&quot;Benign VCF with worsening pain, deformity, or pulmonary dysfunction. Initial treatment&quot;</td>
<td>Usually Appropriate</td>
</tr>
<tr>
<td>&quot;Pathological VCF with ongoing or increasing mechanical pain. Initial treatment&quot;</td>
<td>Usually Appropriate</td>
</tr>
</tbody>
</table>

ACR: American College of Radiology; CT: computed tomography; MRI: magnetic resonance imaging; VCF: vertebral compression fracture.

In 2014, the ACR and 7 other medical specialty associations, including the Society for Interventional Radiology, updated a 2012 joint position statement on percutaneous vertebral augmentation.16 The statement indicated that "percutaneous vertebral augmentation with the use of vertebroplasty or kyphoplasty is a safe, efficacious, and durable procedure in appropriate patients with symptomatic osteoporotic and neoplastic fractures, when performed in accordance with published standards...only when nonoperative medical therapy has not provided adequate pain relief or pain is significantly altering the patient's quality of life."

**Society of Interventional Radiology**

In a 2014 quality improvement guideline for percutaneous vertebroplasty from the Society of Interventional Radiology, failure of medical therapy was defined as follows47:

1. "For a patient rendered nonambulatory as a result of pain from a weakened or fractured vertebral body, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy;
2. For a patient with sufficient pain from a weakened or fractured vertebral body that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or
3. For any patient with a weakened or fractured vertebral body, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level."

**American Academy of Orthopaedic Surgeons**

In 2011, the American Academy of Orthopaedic Surgeons (AAOS) published practice guidelines on the treatment of osteoporotic spinal compression fractures.48 The AAOS approved "a strong recommendation against the use of vertebroplasty for patients who present with an acute osteoporotic spinal compression fracture and are neurologically intact."

**National Institute for Health and Care Excellence**

Reproduction without authorization from Blue Shield of California is prohibited
In 2003, NICE concluded in its guidance on percutaneous vertebroplasty that the current evidence on the safety and efficacy of vertebroplasty for vertebral compression fractures appeared "adequate to support the use of this procedure" to "provide pain relief for people with severe painful osteoporosis with loss of height and/or compression fractures of the vertebral body...." NICE. The guidance also recommended that the procedure be limited to patients whose pain is refractory to more conservative treatment. A 2013 NICE guidance, which was reaffirmed in 2016, indicated that percutaneous vertebroplasty and percutaneous balloon kyphoplasty "are recommended as options for treating osteoporotic vertebral compression fractures" in persons having "severe, ongoing pain after a recent, unhealed vertebral fracture despite optimal pain management" and whose "pain has been confirmed to be at the level of the fracture by physical examination and imaging." NICE

In 2008, NICE issued guidance on the diagnosis and management of adults with metastatic spinal cord compression. NICE. This guidance indicated that vertebroplasty or kyphoplasty should be considered for "patients who have vertebral metastases and no evidence of metastatic spinal cord compression or spinal instability if they have: mechanical pain resistant to conventional pain management, or vertebral body collapse."

**American Society of Pain and Neuroscience**

In 2021, the American Society of Pain and Neuroscience (ASPN) published practice guidelines for the interventional management of cancer-associated pain. The guideline included a best practice statement that stated "vertebral augmentation should be strongly considered for patients with symptomatic vertebral compression fractures from spinal metastases (evidence level 1-A)." However, ASPN noted that there is little data to suggest the superiority of either vertebroplasty or kyphoplasty when treating malignant vertebral compression fractures.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 16.

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02489825</td>
<td>Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?</td>
<td>100</td>
<td>June 2019</td>
</tr>
<tr>
<td>NCT02902250</td>
<td>The Comparative Study About the Effect of Vertebral Body Decompression Procedure and Conservative Treatment for Benign Vertebral Compression Fracture - Prospective Randomized Control Study</td>
<td>80</td>
<td>Feb 2022</td>
</tr>
<tr>
<td>NCT03617094</td>
<td>Early Percutaneous Vertebroplasty Versus Standard Conservative Treatment in Thoracolumbar Vertebral Fractures. Monocentric, Prospective, Randomised and Compared Clinical Study</td>
<td>42</td>
<td>Oct 2020</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

**References**


15. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. TEC Assessments. 2008; Volume 23: Tab 5.


randomized controlled study. Clin Cases Miner Bone Metab. 2016; 13(3): 234-236. PMID 28228788

**Documentation for Clinical Review**

Please provide the following documentation:
- History and physical and/or consultation notes including:
  - Reason for procedure
  - Diagnoses
  - Description of prior treatment and response (including time frame of treatment)
  - Imaging report(s)

Post Service (in addition to the above, please include the following):
- Procedure report
Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT*</td>
<td>0200T</td>
<td>Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed</td>
</tr>
<tr>
<td>CPT*</td>
<td>0201T</td>
<td>Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed</td>
</tr>
<tr>
<td>22510</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic</td>
<td></td>
</tr>
<tr>
<td>22511</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral</td>
<td></td>
</tr>
<tr>
<td>22512</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure)</td>
<td></td>
</tr>
<tr>
<td>HCPCS</td>
<td>C7504</td>
<td>Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance (Code effective 1/1/2023)</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C7505</td>
<td>Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance (Code effective 1/1/2023)</td>
</tr>
</tbody>
</table>

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/14/2001</td>
<td>New Policy Adoption Policy for Vertebroplasty</td>
</tr>
<tr>
<td>10/24/2001</td>
<td>New Policy Adoption Policy for Kyphoplasty</td>
</tr>
<tr>
<td>11/05/2002</td>
<td>Policy Revision Addition of the FDA notification to description</td>
</tr>
<tr>
<td>10/01/2005</td>
<td>Policy Name Change Policy review, title modifications</td>
</tr>
</tbody>
</table>
**Effective Date** | **Action**
--- | ---
10/15/2007 | Policy Revision Policy changed based on expert input and evidence review. Approved under certain conditions (see policy for details).
06/19/2009 | Policy Name Change Combination of two BCBSA medical policies: Percutaneous Vertebroplasty and Sacroplasty (6.01.25) and Percutaneous Kyphoplasty (6.01.38).
07/06/2012 | Policy title change from Percutaneous Kyphoplasty and Vertebroplasty with position change
07/15/2012 | Coding Update
12/15/2014 | Policy title change from Percutaneous Kyphoplasty, Vertebroplasty and Sacroplasty Policy revision with position change
04/08/2015 | Coding update
08/31/2015 | Policy revision without position change
01/01/2016 | Coding update
07/01/2016 | Clarification of policy language
05/01/2017 | Policy revision without position change
07/01/2017 | Policy revision without position change
06/01/2018 | Policy revision without position change
06/01/2019 | Policy revision without position change
06/01/2020 | Annual review. No change to policy statement. Literature review updated.
06/01/2021 | Annual review. Policy statement and literature review updated.
06/01/2022 | Annual review. No change to policy statement. Literature review updated.
03/01/2023 | Coding update
06/01/2023 | Annual review. No change to policy statement. Literature review updated.

**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and
effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*
## Appendix A

### POLICY STATEMENT

**BEFORE**

**Percutaneous Vertebroplasty and Sacroplasty 6.01.25**

**Policy Statement:**

I. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of **any** of the following indications:
   
   A. Symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (e.g., analgesics, physical therapy, and rest) for at least 6 weeks
   
   B. Severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies
      
      1. Vertebral eosinophilic granuloma with spinal instability
      
      2. Vertebral hemangiomas with **both** of the following:
         
         a. Aggressive signs (e.g., myelopathy, radiculopathy, bone fracture, collapse or destruction)
         
         b. Radiation therapy has failed to relieve symptoms

II. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that are less than 6 weeks in duration that have led to hospitalization or persist at a level that prevents ambulation.

III. Percutaneous vertebroplasty is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

IV. Percutaneous sacroplasty is considered **investigational** for all indications, including use in **either** of the following:
   
   A. Sacral insufficiency fractures due to osteoporosis
   
   B. Sacral lesions due to multiple myeloma or metastatic malignancies

**AFTER**

**Percutaneous Vertebroplasty and Sacroplasty 6.01.25**

**Policy Statement:**

I. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of **any** of the following indications:
   
   A. Symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (e.g., analgesics, physical therapy, and rest) for at least 6 weeks
   
   B. Severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies
      
      1. Vertebral eosinophilic granuloma with spinal instability
      
      2. Vertebral hemangiomas with **both** of the following:
         
         a. Aggressive signs (e.g., myelopathy, radiculopathy, bone fracture, collapse or destruction)
         
         b. Radiation therapy has failed to relieve symptoms

II. Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that are less than 6 weeks in duration that have led to hospitalization or persist at a level that prevents ambulation.

III. Percutaneous vertebroplasty is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

IV. Percutaneous sacroplasty is considered **investigational** for all indications, including use in **either** of the following:
   
   A. Sacral insufficiency fractures due to osteoporosis
   
   B. Sacral lesions due to multiple myeloma or metastatic malignancies